Funded Expressions of Interest
1 July 2013 to 31 December 2014
Associate Professor David Anderson
. Burnet Institute. Plasma collection/drying device to facilitate
HIV viral load testing for patients in remote settings.
Professor James Beeson
. Burnet Institute. Carbohydrate inhibitors of HIV - potential microbicides
Dr. Rob Center
. The University of Melbourne. Targeting HIV immunogens to immune cells to
enhance vaccine efficacy
Professor Anthony Cunningham
. Westmead Millennium Institute for Medical Research.
Development of small molecule inhibitors of HIV envelope-Langerin interactions and of HIV uptake
by Langerhans Cells (LCs) as topical (genital) microbicides.
Dr. Russel Diefenbach
. Westmead Millennium Institute for Medical Research. Development of
inhibitors that target dynein-dependent transport of HIV.
Professor Christian Doerig
. Monash University. Human protein kinases essential for hepatitis C
Dr. Mark Douglas
. The University of Sydney. A Pilot Study of Fenofibrate to Improve Hepatitis C
Virus Treatment Response.
Associate Professor Heidi Drummer
. Burnet Institute. Production and evaluation of a CHO cell
derived Delta3 HCV vaccine candidate.
Dr. Lloyd Einsiede
l. Flinders University. The influence of infection with the human T lymphocyte
virus Type 1 on clinical outcomes, virological features and biomarkers of chronic hepatitis B virus
infection in an indigenous Australian population.
Dr. Nicholas Eyre
. University of Adelaide. Hepatitis C virus NS5A protein phosphorylation as a target
of antiviral drug development.
Dr. Karla Helbig
. University of Adelaide. Improving treatment outcomes in individuals with chronic
HCV and steatosis.
Professor Paul Hertzog
. Monash University. Defining the anti-HIV activity of interferon epsilon - a
reproductive tract-specific, hormone-regulated type 1 interferon.
Professor Mark Hogarth
. Burnet Institute. A method of measuring HIV specific immune complexes
and correlation with vaccine responses and disease outcome.
Professor Stephen Kent
. The University of Melbourne. Antibody protection against cell-associated
Dr. Marit Kramski
. The University of Melbourne. Antibody-dependent cel ular cytotoxicity boosting
therapeutic vaccines to purge the HIV reservoir.
Dr. Michaela Lucas
. Murdoch University. T cell and B cell responses to the Delta3 HCV vaccine
Dr. Clovis Palmer
. Burnet Institute. Predicting the rate of CD4+ T cell decline in HIV infected adults.
Dr. Rebecca Pavlos
. Murdoch University. HLA - Associated drug hypersensitivities: Functional basis
of clinical phenotyes and applications to safer drug development.
Dr. Pantelis Poumbourios
. Burnet Institute. Novel HIV-1-like particle vaccine with enhanced
presentation of broadly neutralizing antibody epitopes.
Associate Professor Damian Purcel
. The University of Melbourne. Optimizing new drugs targeting
HIV-1 viral latency.
Dr. Charani Ranasinghe
. The Australian National University. Validation of an effective HIV vaccine
for pre-clinical evaluation.
Professor Andreas Suhrbier
. QIMR Berghofer Medical Research Institute. EcoHIV, a convenient,
biosafety level 2, mouse model for animal testing of HIV vaccines and anti-retroviral drugs.
Associate Professor Kumar Visvanathan
. The University of Melbourne. Interferon stimulating gene
(ISG) induction in the liver of HCV infected patients pre and post treatment.
Dr. Nadia Warner
. Melbourne Health. NTCP-HepG2 cells – Establishing a model system for HBV
infection, fitness and cccDNA.
Associate Professor Amany Zekry
. University of New South Wales. T-cell metabolic pathways as a
predictor of anti-HCV T-cell immune response and outcomes after primary HCV infection.
ZELNORM- tegas erod maleate tablet Novartis Pharmaceuticals Corporation ---------- T2004-53/T2004-54 89015305 ZELNORM® (tegas erod maleate) Tablets Rx only Pres cribing Information DESCRIPTION Zelnorm® (tegaserod maleate) tablets contain tegaserod as the hydrogen maleate salt. As the maleate salt, tegaserod is chemically designated as 3-(5-methoxy-1H-indol-3-ylmethylene)-N-
PRODUCT ANNOUNCEMENT Fluke Ti32 and TiR32 Thermal Imagers and Accessories Introducing a new line of High Definition Thermal Imagers! High definition thermal imagers have never been this affordable… This rugged… Or this easy to use … until now . Fluke is excited to announce the addition of two new, High Definition, thermal imagers to our portf